| Year |
Citation |
Score |
| 2024 |
Amor C, Fernández-Maestre I, Chowdhury S, Ho YJ, Nadella S, Graham C, Carrasco SE, Nnuji-John E, Feucht J, Hinterleitner C, Barthet VJA, Boyer JA, Mezzadra R, Wereski MG, Tuveson DA, ... ... Lowe SW, et al. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Nature Aging. PMID 38267706 DOI: 10.1038/s43587-023-00560-5 |
0.486 |
|
| 2024 |
Leibold J, Tsanov KM, Amor C, Ho YJ, Sánchez-Rivera FJ, Feucht J, Baslan T, Chen HA, Tian S, Simon J, Wuest A, Wilkinson JE, Lowe SW. Somatic mouse models of gastric cancer reveal genotype-specific features of metastatic disease. Nature Cancer. PMID 38177458 DOI: 10.1038/s43018-023-00686-w |
0.772 |
|
| 2023 |
Torborg SR, Grbovic-Huezo O, Singhal A, Holm M, Wu K, Han X, Ho YJ, Haglund C, Mitchell MJ, Lowe SW, Dow LE, Pitter KL, Sanchez-Rivera FJ, Levchenko A, Tammela T. Solid tumor growth depends on an intricate equilibrium of malignant cell states. Biorxiv : the Preprint Server For Biology. PMID 38234855 DOI: 10.1101/2023.12.30.573100 |
0.796 |
|
| 2023 |
Amor C, Fernández-Maestre I, Chowdhury S, Ho YJ, Nadella S, Graham C, Carrasco SE, Nnuji-John E, Feucht J, Hinterleitner C, Barthet VJA, Boyer JA, Mezzadra R, Wereski MG, Tuveson DA, ... ... Lowe SW, et al. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Research Square. PMID 37841853 DOI: 10.21203/rs.3.rs-3385749/v1 |
0.492 |
|
| 2023 |
Katti A, Vega-Pérez A, Foronda M, Zimmerman J, Zafra MP, Granowsky E, Goswami S, Gardner EE, Diaz BJ, Simon JM, Wuest A, Luan W, Fernandez MTC, Kadina AP, Walker JA, ... ... Lowe SW, et al. Generation of precision preclinical cancer models using regulated in vivo base editing. Nature Biotechnology. PMID 37563300 DOI: 10.1038/s41587-023-01900-x |
0.301 |
|
| 2023 |
Sun S, Hong J, You E, Tsanov KM, Chacon-Barahona J, Gioacchino AD, Hoyos D, Li H, Jiang H, Ly H, Marhon S, Murali R, Chanda P, Karacay A, Vabret N, ... ... Lowe SW, et al. Cancer cells co-evolve with retrotransposons to mitigate viral mimicry. Biorxiv : the Preprint Server For Biology. PMID 37292765 DOI: 10.1101/2023.05.19.541456 |
0.775 |
|
| 2023 |
Zhu C, Soto-Feliciano YM, Morris JP, Huang CH, Koche RP, Ho YJ, Banito A, Chen CD, Shroff A, Tian S, Livshits G, Chen CC, Fennell M, Armstrong SA, Allis CD, ... ... Lowe SW, et al. MLL3 regulates the tumor suppressor locus in liver cancer. Elife. 12. PMID 37261974 DOI: 10.7554/eLife.80854 |
0.332 |
|
| 2023 |
Burdziak C, Alonso-Curbelo D, Walle T, Reyes J, Barriga FM, Haviv D, Xie Y, Zhao Z, Zhao CJ, Chen HA, Chaudhary O, Masilionis I, Choo ZN, Gao V, Luan W, ... ... Lowe SW, et al. Epigenetic plasticity cooperates with cell-cell interactions to direct pancreatic tumorigenesis. Science (New York, N.Y.). 380: eadd5327. PMID 37167403 DOI: 10.1126/science.add5327 |
0.306 |
|
| 2023 |
Hu J, Sánchez-Rivera FJ, Wang Z, Johnson GN, Ho YJ, Ganesh K, Umeda S, Gan S, Mujal AM, Delconte RB, Hampton JP, Zhao H, Kottapalli S, de Stanchina E, Iacobuzio-Donahue CA, ... ... Lowe SW, et al. STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma. Nature. PMID 36991128 DOI: 10.1038/s41586-023-05880-5 |
0.811 |
|
| 2023 |
Schwoerer S, Cimino FV, Ros M, Tsanov KM, Ng C, Lowe SW, Carmona-Fontaine C, Thompson CB. Hypoxia potentiates the inflammatory fibroblast phenotype promoted by pancreatic cancer cell-derived cytokines. Cancer Research. PMID 36912618 DOI: 10.1158/0008-5472.CAN-22-2316 |
0.773 |
|
| 2022 |
Barriga FM, Tsanov KM, Ho YJ, Sohail N, Zhang A, Baslan T, Wuest AN, Del Priore I, Meškauskaitė B, Livshits G, Alonso-Curbelo D, Simon J, Chaves-Perez A, Bar-Sagi D, Iacobuzio-Donahue CA, ... ... Lowe SW, et al. MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis. Nature Cancer. PMID 36344707 DOI: 10.1038/s43018-022-00443-5 |
0.777 |
|
| 2022 |
Soto-Feliciano YM, Sanchez-Rivera FJ, Perner F, Barrows DW, Kastenhuber ER, Ho YJ, Carroll TS, Xiong Y, Anand D, Soshnev AA, Gates L, Beytagh MC, Cheon D, Gu SS, Liu XS, ... ... Lowe SW, et al. A molecular switch between mammalian MLL complexes dictates response to Menin-MLL inhibition. Cancer Discovery. PMID 36264143 DOI: 10.1158/2159-8290.CD-22-0416 |
0.797 |
|
| 2022 |
Baslan T, Morris JP, Zhao Z, Reyes J, Ho YJ, Tsanov KM, Bermeo J, Tian S, Zhang S, Askan G, Yavas A, Lecomte N, Erakky A, Varghese AM, Zhang A, ... ... Lowe SW, et al. Ordered and deterministic cancer genome evolution after p53 loss. Nature. PMID 35978189 DOI: 10.1038/s41586-022-05082-5 |
0.77 |
|
| 2022 |
Na F, Pan X, Chen J, Chen X, Wang M, Chi P, You L, Zhang L, Zhong A, Zhao L, Dai S, Zhang M, Wang Y, Wang B, Zheng J, ... ... Lowe SW, et al. KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming. Nature Cancer. PMID 35449309 DOI: 10.1038/s43018-022-00361-6 |
0.392 |
|
| 2022 |
Li X, Huang CH, Sánchez-Rivera FJ, Kennedy MC, Tschaharganeh DF, Morris JP, Montinaro A, O'Rourke KP, Banito A, Wilkinson JE, Chen CC, Ho YJ, Dow LE, Tian S, Luan W, ... ... Lowe SW, et al. A preclinical platform for assessing antitumor effects and systemic toxicities of cancer drug targets. Proceedings of the National Academy of Sciences of the United States of America. 119: e2110557119. PMID 35442775 DOI: 10.1073/pnas.2110557119 |
0.802 |
|
| 2022 |
Sánchez-Rivera FJ, Diaz BJ, Kastenhuber ER, Schmidt H, Katti A, Kennedy M, Tem V, Ho YJ, Leibold J, Paffenholz SV, Barriga FM, Chu K, Goswami S, Wuest AN, Simon JM, ... ... Lowe SW, et al. Base editing sensor libraries for high-throughput engineering and functional analysis of cancer-associated single nucleotide variants. Nature Biotechnology. PMID 35165384 DOI: 10.1038/s41587-021-01172-3 |
0.778 |
|
| 2022 |
Shakiba M, Zumbo P, Espinosa-Carrasco G, Menocal L, Dündar F, Carson SE, Bruno EM, Sanchez-Rivera FJ, Lowe SW, Camara S, Koche RP, Reuter VP, Socci ND, Whitlock B, Tamzalit F, et al. TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. The Journal of Experimental Medicine. 219. PMID 34935874 DOI: 10.1084/jem.20201966 |
0.797 |
|
| 2021 |
Gearty SV, Dündar F, Zumbo P, Espinosa-Carrasco G, Shakiba M, Sanchez-Rivera FJ, Socci ND, Trivedi P, Lowe SW, Lauer P, Mohibullah N, Viale A, DiLorenzo TP, Betel D, Schietinger A. An autoimmune stem-like CD8 T cell population drives type 1 diabetes. Nature. PMID 34847567 DOI: 10.1038/s41586-021-04248-x |
0.775 |
|
| 2021 |
Ricardo-Lax I, Luna JM, Thao TTN, Le Pen J, Yu Y, Hoffmann HH, Schneider WM, Razooky BS, Fernandez-Martinez J, Schmidt F, Weisblum Y, Trüeb BS, Berenguer Veiga I, Schmied K, Ebert N, ... ... Lowe SW, et al. Replication and single-cycle delivery of SARS-CoV-2 replicons. Science (New York, N.Y.). eabj8430. PMID 34648371 DOI: 10.1126/science.abj8430 |
0.78 |
|
| 2021 |
Alonso-Curbelo D, Ho YJ, Burdziak C, Maag JLV, Morris JP, Chandwani R, Chen HA, Tsanov KM, Barriga FM, Luan W, Tasdemir N, Livshits G, Azizi E, Chun J, Wilkinson JE, ... ... Lowe SW, et al. A gene-environment-induced epigenetic program initiates tumorigenesis. Nature. PMID 33536616 DOI: 10.1038/s41586-020-03147-x |
0.767 |
|
| 2020 |
Schneider WM, Luna JM, Hoffmann HH, Sánchez-Rivera FJ, Leal AA, Ashbrook AW, Le Pen J, Ricardo-Lax I, Michailidis E, Peace A, Stenzel AF, Lowe SW, MacDonald MR, Rice CM, Poirier JT. Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks. Cell. PMID 33382968 DOI: 10.1016/j.cell.2020.12.006 |
0.776 |
|
| 2020 |
Hoffmann HH, Sánchez-Rivera FJ, Schneider WM, Luna JM, Soto-Feliciano YM, Ashbrook AW, Le Pen J, Leal AA, Ricardo-Lax I, Michailidis E, Hao Y, Stenzel AF, Peace A, Zuber J, Allis CD, ... Lowe SW, et al. Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors. Cell Host & Microbe. PMID 33357464 DOI: 10.1016/j.chom.2020.12.009 |
0.778 |
|
| 2020 |
Bieging-Rolett KT, Kaiser AM, Morgens DW, Boutelle AM, Seoane JA, Van Nostrand EL, Zhu C, Houlihan SL, Mello SS, Yee BA, McClendon J, Pierce SE, Winters IP, Wang M, Connolly AJ, ... Lowe SW, et al. Zmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program. Molecular Cell. 80: 452-469.e9. PMID 33157015 DOI: 10.1016/j.molcel.2020.10.022 |
0.634 |
|
| 2020 |
Schneider WM, Luna JM, Hoffmann HH, Sánchez-Rivera FJ, Leal AA, Ashbrook AW, Le Pen J, Michailidis E, Ricardo-Lax I, Peace A, Stenzel AF, Lowe SW, MacDonald MR, Rice CM, Poirier JT. Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks. Biorxiv : the Preprint Server For Biology. PMID 33052332 DOI: 10.1101/2020.10.07.326462 |
0.778 |
|
| 2020 |
Chen M, Chen X, Li S, Pan X, Gong Y, Zheng J, Xu J, Zhao C, Zhang Q, Zhang S, Qi L, Wang Z, Shi K, Ding BS, Xue Z, ... ... Lowe SW, et al. An epigenetic mechanism underlying chromosome 17p deletion-driven tumorigenesis. Cancer Discovery. PMID 32978226 DOI: 10.1158/2159-8290.CD-20-0336 |
0.466 |
|
| 2020 |
Hoffmann HH, Schneider WM, Sánchez-Rivera FJ, Luna JM, Ashbrook AW, Soto-Feliciano YM, Leal AA, Le Pen J, Ricardo-Lax I, Michailidis E, Hao Y, Stenzel AF, Peace A, Allis CD, Lowe SW, et al. Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors. Biorxiv : the Preprint Server For Biology. PMID 32935098 DOI: 10.1101/2020.09.11.291716 |
0.775 |
|
| 2020 |
Oni TE, Biffi G, Baker LA, Hao Y, Tonelli C, Somerville TDD, Deschênes A, Belleau P, Hwang CI, Sánchez-Rivera FJ, Cox H, Brosnan E, Doshi A, Lumia RP, Khaledi K, ... ... Lowe SW, et al. SOAT1 promotes mevalonate pathway dependency in pancreatic cancer. The Journal of Experimental Medicine. 217. PMID 32633781 DOI: 10.1084/Jem.20192389 |
0.803 |
|
| 2020 |
Gorelick AN, Sánchez-Rivera FJ, Cai Y, Bielski CM, Biederstedt E, Jonsson P, Richards AL, Vasan N, Penson AV, Friedman ND, Ho YJ, Baslan T, Bandlamudi C, Scaltriti M, Schultz N, ... Lowe SW, et al. Phase and context shape the function of composite oncogenic mutations. Nature. PMID 32461694 DOI: 10.1038/S41586-020-2315-8 |
0.785 |
|
| 2020 |
Leibold J, Ruscetti M, Cao Z, Ho YJ, Baslan T, Zou M, Abida W, Feucht J, Han T, Barriga FM, Tsanov KM, Zamechek L, Kulick A, Amor C, Tian S, ... ... Lowe SW, et al. Somatic tissue engineering in mouse models reveals an actionable role for WNT pathway alterations in prostate cancer metastasis. Cancer Discovery. PMID 32376773 DOI: 10.1158/2159-8290.Cd-19-1242 |
0.781 |
|
| 2020 |
Ruscetti M, Morris JP, Mezzadra R, Russell J, Leibold J, Romesser PB, Simon J, Kulick A, Ho YJ, Fennell M, Li J, Norgard RJ, Wilkinson JE, Alonso-Curbelo D, Sridharan R, ... ... Lowe SW, et al. Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. Cell. PMID 32234521 DOI: 10.1016/J.Cell.2020.03.008 |
0.301 |
|
| 2020 |
Yuan S, Natesan R, Sanchez-Rivera FJ, Li J, Bhanu NV, Yamazoe T, Lin JH, Merrell AJ, Sela Y, Thomas SK, Jiang Y, Plesset JB, Miller EM, Shi J, Garcia BA, ... Lowe SW, et al. Global regulation of the histone mark H3K36me2 underlies epithelial plasticity and metastatic progression. Cancer Discovery. PMID 32188706 DOI: 10.1158/2159-8290.Cd-19-1299 |
0.795 |
|
| 2020 |
Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, Richman LP, Lin J, Sun YH, Liudahl SM, Tobias JW, Lowe S, Coussens LM, Wherry JE, Vonderheide RH, et al. Abstract PR11: Tumor cell-intrinsic factors underlie the heterogeneity of immune infiltration and response to immunotherapy in pancreatic cancer Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm18-Pr11 |
0.398 |
|
| 2020 |
Ganesh K, Basnet H, Kaygusuz Y, Laughney A, He L, Sharma R, O'Rourke K, Reuter V, Huang Y, Masilionis I, Turkekul M, Er E, Manova-Todorova K, Saltz L, Weiser M, ... ... Lowe S, et al. Abstract A12: L1CAM defines the regenerative origin of metastasis initiating cells in colorectal cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-A12 |
0.42 |
|
| 2019 |
Morris JP, Yashinskie JJ, Koche R, Chandwani R, Tian S, Chen CC, Baslan T, Marinkovic ZS, Sánchez-Rivera FJ, Leach SD, Carmona-Fontaine C, Thompson CB, Finley LWS, Lowe SW. α-Ketoglutarate links p53 to cell fate during tumour suppression. Nature. PMID 31534224 DOI: 10.1038/S41586-019-1577-5 |
0.814 |
|
| 2019 |
Loizou E, Banito A, Livshits G, Ho YJ, Koche RP, Sanchez-Rivera FJ, Mayle A, Chen CC, Kinalis S, Bagger FO, Kastenhuber ER, Durham BH, Lowe SW. A gain-of-function p53 mutant oncogene promotes cell fate plasticity and myeloid leukemia through the pluripotency factor Foxh1. Cancer Discovery. PMID 31068365 DOI: 10.1158/2159-8290.CD-18-1391 |
0.815 |
|
| 2019 |
Muto T, Guillamot M, Fang J, Redondo LZ, Choi K, Gong Y, Walker CS, Hueneman K, Bolanos LC, Barreyro L, Lee L, Greis KD, Khodadadi-Jamayran A, Lujambio A, Lowe SW, et al. Innate Immune Signaling Suppresses Acute Leukemia By Modifying MYC Oncogenic Activity Blood. 134: 727-727. DOI: 10.1182/Blood-2019-121423 |
0.354 |
|
| 2018 |
Moon SH, Huang CH, Houlihan SL, Regunath K, Freed-Pastor WA, Morris JP, Tschaharganeh DF, Kastenhuber ER, Barsotti AM, Culp-Hill R, Xue W, Ho YJ, Baslan T, Li X, Mayle A, ... ... Lowe SW, et al. p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression. Cell. PMID 30580964 DOI: 10.1016/J.Cell.2018.11.011 |
0.564 |
|
| 2018 |
Ruscetti M, Leibold J, Bott MJ, Fennell M, Kulick A, Salgado NR, Chen CC, Ho YJ, Sanchez-Rivera FJ, Feucht J, Baslan T, Tian S, Chen HA, Romesser PB, Poirier JT, ... ... Lowe SW, et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science (New York, N.Y.). 362: 1416-1422. PMID 30573629 DOI: 10.1126/Science.Aas9090 |
0.811 |
|
| 2018 |
Faletti L, Peintner L, Neumann S, Sandler S, Grabinger T, Mac Nelly S, Merfort I, Huang CH, Tschaharganeh D, Kang TW, Heinzmann F, D'Artista L, Maurer U, Brunner T, Lowe S, et al. TNFα sensitizes hepatocytes to FasL-induced apoptosis by NFκB-mediated Fas upregulation. Cell Death & Disease. 9: 909. PMID 30185788 DOI: 10.1038/S41419-018-0935-9 |
0.357 |
|
| 2018 |
Zafra MP, Schatoff EM, Katti A, Foronda M, Breinig M, Schweitzer AY, Simon A, Han T, Goswami S, Montgomery E, Thibado J, Kastenhuber ER, Sánchez-Rivera FJ, Shi J, Vakoc CR, ... Lowe SW, et al. Optimized base editors enable efficient editing in cells, organoids and mice. Nature Biotechnology. PMID 29969439 DOI: 10.1038/Nbt.4194 |
0.782 |
|
| 2018 |
Lee SC, North K, Chen C, Kim E, Lu SX, Ki M, Garippa R, Lowe SW, Bradley RK, Abdel-Wahab OI. Dependency of Spliceosomal Mutant MDS on Innate Immune Signaling Blood. 132: 937-937. DOI: 10.1182/Blood-2018-99-111552 |
0.303 |
|
| 2018 |
Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Chadalavada K, DeStanchina E, Nanjangud G, Berger M, Lowe S, Reis-Filho JS, Rosen N, Lito P. Abstract B015: An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B015 |
0.406 |
|
| 2017 |
Álvarez-Fernández M, Sanz-Flores M, Sanz-Castillo B, Salazar-Roa M, Partida D, Zapatero-Solana E, Ali HR, Manchado E, Lowe S, VanArsdale T, Shields D, Caldas C, Quintela-Fandino M, Malumbres M. Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer. Cell Death and Differentiation. PMID 29229993 DOI: 10.1038/S41418-017-0024-0 |
0.392 |
|
| 2017 |
Jacamo R, Davis RE, Ling X, Sonnylal S, Wang Z, Ma W, Zhang M, Ruvolo P, Ruvolo V, Wang RY, McQueen T, Lowe S, Zuber J, Kornblau SM, Konopleva M, et al. Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. Oncotarget. 8: 83354-83369. PMID 29137349 DOI: 10.18632/Oncotarget.19042 |
0.346 |
|
| 2017 |
Kastenhuber ER, Lowe SW. Putting p53 in Context. Cell. 170: 1062-1078. PMID 28886379 DOI: 10.1016/j.cell.2017.08.028 |
0.307 |
|
| 2017 |
Pelossof R, Fairchild L, Huang CH, Widmer C, Sreedharan VT, Sinha N, Lai DY, Guan Y, Premsrirut PK, Tschaharganeh DF, Hoffmann T, Thapar V, Xiang Q, Garippa RJ, Rätsch G, ... ... Lowe SW, et al. Prediction of potent shRNAs with a sequential classification algorithm. Nature Biotechnology. PMID 28263295 DOI: 10.1038/Nbt.3807 |
0.668 |
|
| 2017 |
Valerio DG, Xu H, Chen CW, Hoshii T, Eisold ME, Delaney C, Cusan M, Deshpande AJ, Huang CH, Lujambio A, Zheng YG, Zuber J, Pandita TK, Lowe SW, Armstrong SA. Histone acetyltransferase activity of MOF is required for MLL-AF9 leukemogenesis. Cancer Research. PMID 28202522 DOI: 10.1158/0008-5472.Can-16-2374 |
0.322 |
|
| 2017 |
Fraile JM, Manchado E, Lujambio A, Quesada V, Campos-Iglesias D, Webb T, Lowe SW, Lopez-Otin C, Freije JM. USP39 Deubiquitinase Is Essential for KRAS-Driven cancer. The Journal of Biological Chemistry. PMID 28154181 DOI: 10.1074/Jbc.M116.762757 |
0.315 |
|
| 2017 |
Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, Shah N, Adams EJ, Abida W, Watson PA, Prandi D, ... ... Lowe SW, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science (New York, N.Y.). 355: 84-88. PMID 28059768 DOI: 10.1126/Science.Aah4307 |
0.325 |
|
| 2017 |
Manchado E, Huang CH, Tasdemir N, Tschaharganeh DF, Wilkinson JE, Lowe SW. A Pipeline for Drug Target Identification and Validation. Cold Spring Harbor Symposia On Quantitative Biology. PMID 28057848 DOI: 10.1101/sqb.2016.81.031096 |
0.356 |
|
| 2017 |
Liu Y, Chen C, Xu Z, Niu T, Lowe S. The impact of ALOX cluster loss in chromosome 17p deletions on cancer Genes and Diseases. 4: 12-13. DOI: 10.1016/J.Gendis.2016.10.008 |
0.434 |
|
| 2016 |
Tschaharganeh DF, Xue W, Calvisi DF, Evert M, Michurina TV, Dow LE, Banito A, Katz SF, Kastenhuber ER, Weissmueller S, Huang CH, Lechel A, Andersen JB, Capper D, Zender L, ... ... Lowe SW, et al. p53-Dependent Nestin Regulation Links Tumor Suppression to Cellular Plasticity in Liver Cancer. Cell. 165: 1546-1547. PMID 27259155 DOI: 10.1016/j.cell.2016.05.058 |
0.549 |
|
| 2016 |
Tschaharganeh DF, Bosbach B, Lowe SW. Coordinated Tumor Suppression by Chromosome 8p. Cancer Cell. 29: 617-9. PMID 27165739 DOI: 10.1016/j.ccell.2016.04.011 |
0.306 |
|
| 2016 |
Tasdemir N, Banito A, Roe JS, Alonso-Curbelo D, Camiolo M, Tschaharganeh DF, Huang CH, Aksoy O, Bolden JE, Chen CC, Fennell M, Thapar V, Chicas A, Vakoc CR, Lowe SW. BRD4 connects enhancer remodeling to senescence immune surveillance. Cancer Discovery. PMID 27099234 DOI: 10.1158/2159-8290.Cd-16-0217 |
0.792 |
|
| 2016 |
Liu Y, Chen C, Xu Z, Scuoppo C, Rillahan CD, Gao J, Spitzer B, Bosbach B, Kastenhuber ER, Baslan T, Ackermann S, Cheng L, Wang Q, Niu T, Schultz N, ... ... Lowe SW, et al. Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. Nature. PMID 26982726 DOI: 10.1038/Nature17157 |
0.425 |
|
| 2016 |
Premsrirut P, Martin G, Dow L, Kim S, Zuber J, Hannon G, Lowe S. RNAi and CRISPR/Cas9 based in vivo models for drug discovery European Journal of Cancer. 61: S208. DOI: 10.1182/Blood.V130.Suppl_1.5568.5568 |
0.733 |
|
| 2016 |
Premsrirut PK, Martin G, Dow L, Kim SY, Zuber J, Lowe S, Hannon G. Abstract 4188: RNAi and CRISPR/Cas9 basedin vivomodels for drug discovery Cancer Research. 76: 4188-4188. DOI: 10.1158/1538-7445.Am2016-4188 |
0.677 |
|
| 2015 |
Lowe S, Cifra A. Exploring cell apoptosis and senescence to understand and treat cancer: an interview with Scott Lowe. Disease Models & Mechanisms. 8: 1345-8. PMID 26512122 DOI: 10.1242/Dmm.023531 |
0.399 |
|
| 2015 |
Dow LE, O'Rourke KP, Simon J, Tschaharganeh DF, van Es JH, Clevers H, Lowe SW. Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer. Cell. 161: 1539-52. PMID 26091037 DOI: 10.1016/J.Cell.2015.05.033 |
0.326 |
|
| 2015 |
Li J, Chanrion M, Sawey E, Wang T, Chow E, Tward A, Su Y, Xue W, Lucito R, Zender L, Lowe SW, Bishop JM, Powers S. Reciprocal interaction of Wnt and RXR-α pathways in hepatocyte development and hepatocellular carcinoma. Plos One. 10: e0118480. PMID 25738607 DOI: 10.1371/Journal.Pone.0118480 |
0.494 |
|
| 2015 |
Appelmann I, Rillahan CD, de Stanchina E, Carbonetti G, Chen C, Lowe SW, Sherr CJ. Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL. Blood. 125: 1444-51. PMID 25499760 DOI: 10.1182/Blood-2014-09-601062 |
0.386 |
|
| 2015 |
Jacamo RO, Mu H, Zhang Q, Chachad D, Zhiqiang W, Ma W, Zhang M, Mak PY, Mak D, Ruvolo P, McQueen T, Lowe S, Zuber J, Eulberg D, Kruschinski A, et al. Effects of CCL2/CCR2 Blockade in Acute Myeloid Leukemia Blood. 126: 1348-1348. DOI: 10.1182/Blood.V126.23.1348.1348 |
0.385 |
|
| 2015 |
Premsrirut PK, Wang C, Yang Y, Pelossof R, Leslie C, Fellmann C, Dow L, Zuber J, Lowe S. Abstract B37: RNAi and CRISPR/Cas9-based in vivo models for drug discovery Cancer Research. 78: 4188-4188. DOI: 10.1158/1538-7445.Mousemodels17-B37 |
0.745 |
|
| 2014 |
Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J, Bohin N, Wen T, Kogan SC, Haigis KM, Sampath D, Lowe S, Shannon K, Li Q. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood. 124: 3947-55. PMID 25361812 DOI: 10.1182/Blood-2014-05-574582 |
0.643 |
|
| 2014 |
Tschaharganeh DF, Xue W, Calvisi DF, Evert M, Michurina TV, Dow LE, Banito A, Katz SF, Kastenhuber ER, Weissmueller S, Huang CH, Lechel A, Andersen JB, Capper D, Zender L, ... ... Lowe SW, et al. p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell. 158: 579-92. PMID 25083869 DOI: 10.1016/J.Cell.2014.05.051 |
0.59 |
|
| 2014 |
Senturk S, Yao Z, Camiolo M, Stiles B, Rathod T, Walsh AM, Nemajerova A, Lazzara MJ, Altorki NK, Krainer A, Moll UM, Lowe SW, Cartegni L, Sordella R. p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state. Proceedings of the National Academy of Sciences of the United States of America. 111: E3287-96. PMID 25074920 DOI: 10.1073/Pnas.1321640111 |
0.794 |
|
| 2014 |
Miething C, Scuoppo C, Bosbach B, Appelmann I, Nakitandwe J, Ma J, Wu G, Lintault L, Auer M, Premsrirut PK, Teruya-Feldstein J, Hicks J, Benveniste H, Speicher MR, Downing JR, ... Lowe SW, et al. PTEN action in leukaemia dictated by the tissue microenvironment. Nature. 510: 402-6. PMID 24805236 DOI: 10.1038/Nature13239 |
0.72 |
|
| 2014 |
Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, Shroff AS, Dickins RA, Vakoc CR, Bradner JE, Stock W, LeBeau MM, Shannon KM, Kogan S, Zuber J, ... Lowe SW, et al. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia Cancer Cell. 25: 652-665. PMID 24794707 DOI: 10.1016/J.Ccr.2014.03.016 |
0.359 |
|
| 2014 |
Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, Saborowski M, Kastenhuber E, Fellmann C, Ohara K, Morikami K, Miura T, Lukacs C, Ishii N, Lowe S, et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell. 25: 697-710. PMID 24746704 DOI: 10.1016/J.Ccr.2014.03.011 |
0.342 |
|
| 2014 |
Weissmueller S, Manchado E, Saborowski M, Morris JP, Wagenblast E, Davis CA, Moon SH, Pfister NT, Tschaharganeh DF, Kitzing T, Aust D, Markert EK, Wu J, Grimmond SM, Pilarsky C, ... ... Lowe SW, et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Cell. 157: 382-94. PMID 24725405 DOI: 10.1016/J.Cell.2014.01.066 |
0.356 |
|
| 2014 |
Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J, Bohin N, Wen T, Kogan SC, Haigis KM, Lowe SW, Shannon K, Li Q. Preclinical Efficacy of MEK Inhibition in Nras Mutant Acute Myeloid Leukemia Blood. 124: 3753-3753. DOI: 10.1182/Blood.V124.21.3753.3753 |
0.597 |
|
| 2014 |
Premsrirut P, Dow L, Hannon G, Zuber J, Lowe S, Zender L, Fellmann C. Abstract PR07: RNAi mouse models: Revolutionizing drug discovery in vivo Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Modorg-Pr07 |
0.753 |
|
| 2014 |
Castel P, Juric D, Won H, Ainscough B, Ellis H, Ebbesen S, Griffith M, Griffith O, Gopakumar I, Sgroi D, Isakoff S, Mardis E, Solit D, Lowe S, Quadt C, et al. Abstract LB-327: Loss of PTEN leads to clinical resistance to the PI3Kα inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-327 |
0.381 |
|
| 2014 |
Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Fellman C, Ohara K, Morikami K, Miura T, Lucas C, Ishii N, Lowe S, Rosen N. Abstract 4758: Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors Cancer Research. 74: 4758-4758. DOI: 10.1158/1538-7445.Am2014-4758 |
0.358 |
|
| 2014 |
Wuestefeld T, Pesic M, Kang T, Malek N, Premsrirut P, Lowe S, Zender L. Development of shRNA transgenic mice for preclinical studies of the MKK4 regeneration kinase Zeitschrift FüR Gastroenterologie. 52. DOI: 10.1055/s-0033-1360855 |
0.664 |
|
| 2013 |
Lu C, Venneti S, Akalin A, Fang F, Ward PS, Dematteo RG, Intlekofer AM, Chen C, Ye J, Hameed M, Nafa K, Agaram NP, Cross JR, Khanin R, Mason CE, ... ... Lowe SW, et al. Induction of sarcomas by mutant IDH2. Genes & Development. 27: 1986-98. PMID 24065766 DOI: 10.1101/Gad.226753.113 |
0.399 |
|
| 2013 |
Chen C, Liu Y, Lu C, Cross JR, Morris JP, Shroff AS, Ward PS, Bradner JE, Thompson C, Lowe SW. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes & Development. 27: 1974-85. PMID 24065765 DOI: 10.1101/Gad.226613.113 |
0.482 |
|
| 2013 |
Premsrirut PK, Dow LE, Park Y, Hannon GJ, Lowe SW. Creating transgenic shRNA mice by recombinase-mediated cassette exchange Cold Spring Harbor Protocols. 2013: 835-842. PMID 24003198 DOI: 10.1101/Pdb.Prot077057 |
0.711 |
|
| 2013 |
Liu Y, Scuoppo C, Lowe S. Abstract B34: The impact of chromosome 17p loss on cancer Cancer Research. 73. DOI: 10.1158/1538-7445.Fbcr13-B34 |
0.416 |
|
| 2013 |
Hein N, Drygin D, O'Brien S, Cullinane C, Matthews G, Chesi M, Bergsagel L, Zuber J, Lowe S, Johnstone R, Pearson R, McArthur G, Hannan R. Abstract B16: Inhibition of RNA Polymerase I transcription by CX-5461 as a therapeutic strategy for the cancer-specific activation of p53 in highly refractory haematological malignancies Cancer Research. 73. DOI: 10.1158/1538-7445.Fbcr13-B16 |
0.428 |
|
| 2012 |
Aksoy O, Chicas A, Zeng T, Zhao Z, McCurrach M, Wang X, Lowe SW. The atypical E2F family member E2F7 couples the p53 and RB pathways during cellular senescence. Genes & Development. 26: 1546-57. PMID 22802529 DOI: 10.1101/gad.196238.112 |
0.317 |
|
| 2012 |
Bywater MJ, Poortinga G, Sanij E, Hein N, Peck A, Cullinane C, Wall M, Cluse L, Drygin D, Anderes K, Huser N, Proffitt C, Bliesath J, Haddach M, Schwaebe MK, ... ... Lowe SW, et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell. 22: 51-65. PMID 22789538 DOI: 10.1016/j.ccr.2012.05.019 |
0.329 |
|
| 2012 |
Lin CJ, Nasr Z, Premsrirut PK, Porco JA, Hippo Y, Lowe SW, Pelletier J. Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. Cell Reports. 1: 325-33. PMID 22573234 DOI: 10.1016/J.Celrep.2012.02.010 |
0.722 |
|
| 2012 |
Xue W, Kitzing T, Roessler S, Zuber J, Krasnitz A, Schultz N, Revill K, Weissmueller S, Rappaport AR, Simon J, Zhang J, Luo W, Hicks J, Zender L, Wang XW, ... ... Lowe SW, et al. A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proceedings of the National Academy of Sciences of the United States of America. 109: 8212-7. PMID 22566646 DOI: 10.1073/Pnas.1206062109 |
0.58 |
|
| 2012 |
Dow LE, Premsrirut PK, Zuber J, Fellmann C, McJunkin K, Miething C, Park Y, Dickins RA, Hannon GJ, Lowe SW. A pipeline for the generation of shRNA transgenic mice Nature Protocols. 7: 374-393. PMID 22301776 DOI: 10.1038/Nprot.2011.446 |
0.696 |
|
| 2012 |
Premsrirut P, Fellmann C, Dow L, Lowe S, Zuber J, Hannon G. 45 Next Generation RNAi Mouse Models for Drug Discovery and Toxicology Assessment European Journal of Cancer. 48: 16. DOI: 10.1016/S0959-8049(12)71843-9 |
0.665 |
|
| 2012 |
Premsrirut P, Fellmann C, Hannon G, Lowe S, Zuber J, Elledge S. 58 Proffered Paper: Next Generation RNAi Mouse Models for Drug Discovery and Toxicology Assessment European Journal of Cancer. 48: S14. DOI: 10.1016/S0959-8049(12)70762-1 |
0.663 |
|
| 2011 |
Chien Y, Scuoppo C, Wang X, Fang X, Balgley B, Bolden JE, Premsrirut P, Luo W, Chicas A, Lee CS, Kogan SC, Lowe SW. Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes & Development. 25: 2125-36. PMID 21979375 DOI: 10.1101/Gad.17276711 |
0.724 |
|
| 2011 |
Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV, Shi J, Weissmueller S, Fellmann C, Fellman C, Taylor MJ, Weissenboeck M, Graeber TG, Kogan SC, Vakoc CR, ... Lowe SW, et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes & Development. 25: 1628-40. PMID 21828272 DOI: 10.1101/Gad.17269211 |
0.472 |
|
| 2011 |
Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, ... ... Lowe SW, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 478: 524-8. PMID 21814200 DOI: 10.1038/Nature10334 |
0.324 |
|
| 2011 |
McJunkin K, Mazurek A, Premsrirut PK, Zuber J, Dow LE, Simon J, Stillman B, Lowe SW. Reversible suppression of an essential gene in adult mice using transgenic RNA interference. Proceedings of the National Academy of Sciences of the United States of America. 108: 7113-8. PMID 21482754 DOI: 10.1073/Pnas.1104097108 |
0.725 |
|
| 2011 |
Premsrirut PK, Dow LE, Kim SY, Camiolo M, Malone CD, Miething C, Scuoppo C, Zuber J, Dickins RA, Kogan SC, Shroyer KR, Sordella R, Hannon GJ, Lowe SW. A rapid and scalable system for studying gene function in mice using conditional RNA interference Cell. 145: 145-158. PMID 21458673 DOI: 10.1016/J.Cell.2011.03.012 |
0.802 |
|
| 2011 |
Karni-Schmidt O, Castillo-Martin M, Shen TH, HuaiShen T, Gladoun N, Domingo-Domenech J, Sanchez-Carbayo M, Li Y, Lowe S, Prives C, Cordon-Cardo C. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. The American Journal of Pathology. 178: 1350-60. PMID 21356385 DOI: 10.1016/J.Ajpath.2010.11.061 |
0.407 |
|
| 2011 |
Zuber J, McJunkin K, Fellmann C, Dow LE, Taylor MJ, Hannon GJ, Lowe SW. Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi Nature Biotechnology. 29: 79-85. PMID 21131983 DOI: 10.1038/Nbt.1720 |
0.303 |
|
| 2011 |
Hein N, Bywater MJ, Stanley K, Verbrugge I, Cullinane C, Baker A, Zuber H, Rappaport A, Drygin D, Huser N, Bliesath J, Ryckman DM, Rice WG, Lowe SW, Johnstone RW, et al. Inhibition of RNA Polymerase I Transcription by CX-5461 As a Therapeutic Strategy for the Cancer-Specific Activation of p53 in MLL-Rearranged Acute Myeloid Leukemias Blood. 118: 1548-1548. DOI: 10.1182/BLOOD.V118.21.1548.1548 |
0.322 |
|
| 2011 |
Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. Erratum: Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas Nature. 473: 544-544. DOI: 10.1038/nature09909 |
0.466 |
|
| 2010 |
Takiguchi M, James C, Josefsson EC, Carmichael CL, Premsrirut PK, Lowe SW, Hamilton JR, Huang DC, Kile BT, Dickins RA. Transgenic, inducible RNAi in megakaryocytes and platelets in mice. Journal of Thrombosis and Haemostasis : Jth. 8: 2751-6. PMID 21138522 DOI: 10.1111/J.1538-7836.2010.04077.X |
0.704 |
|
| 2010 |
Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K, Lowe SW. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes & Development. 24: 1389-402. PMID 20595231 DOI: 10.1101/Gad.1940710 |
0.3 |
|
| 2010 |
Bazarov AV, Van Sluis M, Hines WC, Bassett E, Beliveau A, Campeau E, Mukhopadhyay R, Lee WJ, Melodyev S, Zaslavsky Y, Lee L, Rodier F, Chicas A, Lowe SW, Benhattar J, et al. p16(INK4a) -mediated suppression of telomerase in normal and malignant human breast cells. Aging Cell. 9: 736-46. PMID 20569236 DOI: 10.1111/J.1474-9726.2010.00599.X |
0.33 |
|
| 2010 |
Chicas A, Wang X, Zhang C, McCurrach M, Zhao Z, Mert O, Dickins RA, Narita M, Zhang M, Lowe SW. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell. 17: 376-87. PMID 20385362 DOI: 10.1016/J.Ccr.2010.01.023 |
0.334 |
|
| 2010 |
Vakoc C, Zuber J, Lowe S, Wang E, Rappaport A, Shi J. An RNAi Screen Reveals a Pattern of Addiction to Epigenetic Pathways That Distinguishes MLL-AF9 Leukemia From Normal Hematopoietic Cells Blood. 116: 65-65. DOI: 10.1182/Blood.V116.21.65.65 |
0.433 |
|
| 2010 |
Bazarov A, Korobochkina I, Bosire M, Hines C, Mukhopadhyay R, Lee WJ, Chicas A, Lowe S, Yaswen P. Abstract 3210: pRb, but not p107 or p130, is required for full induction of p16INK4a in human mammary epithelial cells Cancer Research. 70: 3210-3210. DOI: 10.1158/1538-7445.Am10-3210 |
0.394 |
|
| 2009 |
Liu LX, Lee NP, Chan VW, Xue W, Zender L, Zhang C, Mao M, Dai H, Wang XL, Xu MZ, Lee TK, Ng IO, Chen Y, Kung HF, Lowe SW, et al. Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology (Baltimore, Md.). 50: 1453-63. PMID 19676131 DOI: 10.1002/Hep.23143 |
0.522 |
|
| 2009 |
Laska MJ, Lowe SW, Zender L, Hearn S, Vogel U, Jensen UB, Bric A, Nexø BA. Enforced expression of PPP1R13L increases tumorigenesis and invasion through p53-dependent and p53-independent mechanisms. Molecular Carcinogenesis. 48: 832-42. PMID 19263435 DOI: 10.1038/Npre.2008.2004.1 |
0.377 |
|
| 2009 |
Pardee T, Zuber J, Lowe S. The Flt3 ITD Accelerates An Already Established Myeloid Leukemia and Alters Chemotherapy Response In Vitro and In Vivo in a p53 Dependent Manner. Blood. 114: 1719-1719. DOI: 10.1182/Blood.V114.22.1719.1719 |
0.361 |
|
| 2008 |
Krizhanovsky V, Xue W, Zender L, Yon M, Hernando E, Lowe SW. Implications of cellular senescence in tissue damage response, tumor suppression, and stem cell biology. Cold Spring Harbor Symposia On Quantitative Biology. 73: 513-22. PMID 19150958 DOI: 10.1101/Sqb.2008.73.048 |
0.581 |
|
| 2008 |
Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, Kubicka S, Luk JM, Schirmacher P, McCombie WR, Wigler M, Hicks J, Hannon GJ, Powers S, ... Lowe SW, et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell. 135: 852-64. PMID 19012953 DOI: 10.1016/J.Cell.2008.09.061 |
0.596 |
|
| 2008 |
Gyrd-Hansen M, Darding M, Miasari M, Santoro MM, Zender L, Xue W, Tenev T, da Fonseca PCA, Zvelebil M, Bujnicki JM, Lowe S, Silke J, Meier P. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-κB as well as cell survival and oncogenesis Nature Cell Biology. 10: 1309-1317. PMID 18931663 DOI: 10.1038/Ncb1789 |
0.553 |
|
| 2008 |
Mavrakis KJ, Zhu H, Silva RL, Mills JR, Teruya-Feldstein J, Lowe SW, Tam W, Pelletier J, Wendel HG. Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes & Development. 22: 2178-88. PMID 18708578 DOI: 10.1101/Gad.1690808 |
0.311 |
|
| 2008 |
Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, Hemann MT. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America. 105: 9053-8. PMID 18574145 DOI: 10.1073/Pnas.0803513105 |
0.551 |
|
| 2008 |
Xue W, Krasnitz A, Lucito R, Sordella R, Vanaelst L, Cordon-Cardo C, Singer S, Kuehnel F, Wigler M, Powers S, Zender L, Lowe SW. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes & Development. 22: 1439-44. PMID 18519636 DOI: 10.1101/Gad.1672608 |
0.576 |
|
| 2008 |
Jones L, Sevcikova S, Phan V, Jain S, Shieh A, Dubansky J, Li M, Maunakea ML, Zhu G, Tennant TR, Lowe S, Le MM, Kogan SC. Myc Drives Chromosomal Gain in Acute Myeloid Leukemia Blood. 112: 792-792. DOI: 10.1182/Blood.V112.11.792.792 |
0.326 |
|
| 2007 |
Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Teruya-Feldstein J, Pelletier J, Lowe SW. Dissecting eIF4E action in tumorigenesis. Genes & Development. 21: 3232-7. PMID 18055695 DOI: 10.1101/Gad.1604407 |
0.325 |
|
| 2007 |
Ha L, Ichikawa T, Anver M, Dickins R, Lowe S, Sharpless NE, Krimpenfort P, Depinho RA, Bennett DC, Sviderskaya EV, Merlino G. ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proceedings of the National Academy of Sciences of the United States of America. 104: 10968-73. PMID 17576930 DOI: 10.1073/Pnas.0611638104 |
0.421 |
|
| 2007 |
Dickins RA, McJunkin K, Hernando E, Premsrirut PK, Krizhanovsky V, Burgess DJ, Kim SY, Cordon-Cardo C, Zender L, Hannon GJ, Lowe SW. Tissue-specific and reversible RNA interference in transgenic mice. Nature Genetics. 39: 914-21. PMID 17572676 DOI: 10.1038/Ng2045 |
0.716 |
|
| 2007 |
He L, He X, Lim LP, De Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, et al. A microRNA component of the p53 tumour suppressor network Nature. 447: 1130-1134. PMID 17554337 DOI: 10.1038/Nature05939 |
0.506 |
|
| 2007 |
Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L, Williams S, Wiegmans AP, Dear AE, Scott CL, Pellegrini M, Wei A, Richon VM, Marks PA, Lowe SW, et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 104: 8071-6. PMID 17470784 DOI: 10.1073/pnas.0702294104 |
0.309 |
|
| 2007 |
Feng Z, Hu W, de Stanchina E, Teresky AK, Jin S, Lowe S, Levine AJ. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Research. 67: 3043-53. PMID 17409411 DOI: 10.1158/0008-5472.Can-06-4149 |
0.364 |
|
| 2007 |
Scott CL, Gil J, Hernando E, Teruya-Feldstein J, Narita M, Martínez D, Visakorpi T, Mu D, Cordon-Cardo C, Peters G, Beach D, Lowe SW. Role of the chromobox protein CBX7 in lymphomagenesis. Proceedings of the National Academy of Sciences of the United States of America. 104: 5389-94. PMID 17374722 DOI: 10.1073/pnas.0608721104 |
0.302 |
|
| 2007 |
Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 445: 656-60. PMID 17251933 DOI: 10.1038/Nature05529 |
0.571 |
|
| 2007 |
Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, Lowe SW, Knudsen ES. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. The Journal of Clinical Investigation. 117: 218-28. PMID 17160137 DOI: 10.1172/Jci28803 |
0.325 |
|
| 2006 |
Lakshmi B, Hall IM, Egan C, Alexander J, Leotta A, Healy J, Zender L, Spector MS, Xue W, Lowe SW, Wigler M, Lucito R. Mouse genomic representational oligonucleotide microarray analysis: detection of copy number variations in normal and tumor specimens. Proceedings of the National Academy of Sciences of the United States of America. 103: 11234-9. PMID 16844783 DOI: 10.1073/Pnas.0602984103 |
0.509 |
|
| 2006 |
Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, Mu D, Lucito R, Powers S, Lowe SW. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 125: 1253-67. PMID 16814713 DOI: 10.1016/J.Cell.2006.05.030 |
0.575 |
|
| 2006 |
Hemann MT, Lowe SW. The p53-Bcl-2 connection. Cell Death and Differentiation. 13: 1256-9. PMID 16710363 DOI: 10.1038/Sj.Cdd.4401962 |
0.348 |
|
| 2006 |
Wendel HG, De Stanchina E, Cepero E, Ray S, Emig M, Fridman JS, Veach DR, Bornmann WG, Clarkson B, McCombie WR, Kogan SC, Hochhaus A, Lowe SW. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition Proceedings of the National Academy of Sciences of the United States of America. 103: 7444-7449. PMID 16651519 DOI: 10.1073/Pnas.0602402103 |
0.329 |
|
| 2005 |
Zender L, Xue W, Cordón-Cardo C, Hannon GJ, Lucito R, Powers S, Flemming P, Spector MS, Lowe SW. Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. Cold Spring Harbor Symposia On Quantitative Biology. 70: 251-61. PMID 16869761 DOI: 10.1101/Sqb.2005.70.059 |
0.537 |
|
| 2005 |
Fernández Y, Verhaegen M, Miller TP, Rush JL, Steiner P, Opipari AW, Lowe SW, Soengas MS. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Research. 65: 6294-304. PMID 16024631 DOI: 10.1158/0008-5472.Can-05-0686 |
0.334 |
|
| 2005 |
Finnberg N, Gruber JJ, Fei P, Rudolph D, Bric A, Kim SH, Burns TF, Ajuha H, Page R, Wu GS, Chen Y, McKenna WG, Bernhard E, Lowe S, Mak T, et al. DR5 knockout mice are compromised in radiation-induced apoptosis. Molecular and Cellular Biology. 25: 2000-13. PMID 15713653 DOI: 10.1128/Mcb.25.5.2000-2013.2005 |
0.349 |
|
| 2005 |
Lowe S. Evading p53 action during tumor development and therapy Breast Cancer Research. 7: 1-1. DOI: 10.1186/Bcr1074 |
0.453 |
|
| 2004 |
Hernando E, Nahlé Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, Lowe SW, Cordon-Cardo C. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature. 430: 797-802. PMID 15306814 DOI: 10.1038/Nature02820 |
0.799 |
|
| 2004 |
Hemann MT, Zilfou JT, Zhao Z, Burgess DJ, Hannon GJ, Lowe SW. Suppression of tumorigenesis by the p53 target PUMA. Proceedings of the National Academy of Sciences of the United States of America. 101: 9333-8. PMID 15192153 DOI: 10.1073/Pnas.0403286101 |
0.311 |
|
| 2003 |
Narita M, N?nez S, Heard E, Narita M, Lin AW, Hearn SA, Spector DL, Hannon GJ, Lowe SW. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 113: 703-16. PMID 12809602 DOI: 10.1016/S0092-8674(03)00401-X |
0.331 |
|
| 2003 |
Kondo S, Lu Y, Debbas M, Lin AW, Sarosi I, Itie A, Wakeham A, Tuan J, Saris C, Elliott G, Ma W, Benchimol S, Lowe SW, Mak TW, Thukral SK. Characterization of cells and gene-targeted mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1). Proceedings of the National Academy of Sciences of the United States of America. 100: 5431-6. PMID 12702766 DOI: 10.1073/Pnas.0530308100 |
0.303 |
|
| 2003 |
Mu D, Chen L, Zhang X, See LH, Koch CM, Yen C, Tong JJ, Spiegel L, Nguyen KC, Servoss A, Peng Y, Pei L, Marks JR, Lowe S, Hoey T, et al. Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell. 3: 297-302. PMID 12676587 DOI: 10.1016/S1535-6108(03)00054-0 |
0.317 |
|
| 2003 |
Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: progress and puzzles. Current Opinion in Genetics & Development. 13: 77-83. PMID 12573439 DOI: 10.1016/S0959-437X(02)00013-8 |
0.32 |
|
| 2003 |
Hemann MT, Fridman JS, Zilfou JT, Hernando E, Paddison PJ, Cordon-Cardo C, Hannon GJ, Lowe SW. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nature Genetics. 33: 396-400. PMID 12567186 DOI: 10.1038/Ng1091 |
0.326 |
|
| 2002 |
Nahle Z, Polakoff J, Davuluri RV, McCurrach ME, Jacobson MD, Narita M, Zhang MQ, Lazebnik Y, Bar-Sagi D, Lowe SW. Direct coupling of the cell cycle and cell death machinery by E2F. Nature Cell Biology. 4: 859-64. PMID 12389032 DOI: 10.1038/Ncb868 |
0.774 |
|
| 2002 |
Hirao A, Cheung A, Duncan G, Girard PM, Elia AJ, Wakeham A, Okada H, Sarkissian T, Wong JA, Sakai T, De Stanchina E, Bristow RG, Suda T, Lowe SW, Jeggo PA, et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Molecular and Cellular Biology. 22: 6521-32. PMID 12192050 DOI: 10.1128/Mcb.22.18.6521-6532.2002 |
0.308 |
|
| 2000 |
Attardi LD, Reczek EE, Cosmas C, Demicco EG, McCurrach ME, Lowe SW, Jacks T. PERP, an apoptosis-associated target of p53, in a novel member of the PMP-22/gas3 family Genes and Development. 14: 704-718. PMID 10733530 DOI: 10.1101/Gad.14.6.704 |
0.74 |
|
| 1998 |
Nikiforov MA, Kwek SS, Mehta R, Artwohl JE, Lowe SW, Gupta TD, Deichman GI, Gudkov AV. Suppression of apoptosis by bcl-2 does not prevent p53-mediated control of experimental metastasis and anchorage dependence. Oncogene. 15: 3007-12. PMID 9444949 DOI: 10.1038/Sj.Onc.1201723 |
0.309 |
|
| 1997 |
Samuelson AV, Lowe SW. Selective induction of p53 and chemosensitivity in RB-deficient cells by E1A mutants unable to bind the RB-related proteins. Proceedings of the National Academy of Sciences of the United States of America. 94: 12094-9. PMID 9342368 DOI: 10.1073/pnas.94.22.12094 |
0.3 |
|
| 1997 |
Lanni JS, Lowe SW, Licitra EJ, Liu JO, Jacks T. p53-independent apoptosis induced by paclitaxel through an indirect mechanism Proceedings of the National Academy of Sciences of the United States of America. 94: 9679-9683. PMID 9275183 DOI: 10.1073/Pnas.94.18.9679 |
0.638 |
|
| 1997 |
Lowe SW, Jacks T. p53 and treatment of bladder cancer Nature. 385: 124-125. DOI: 10.1038/385124a0 |
0.582 |
|
| 1996 |
Lowe SW. Cancer therapy and p53. Current Opinion in Oncology. 7: 547-53. PMID 8547404 DOI: 10.1097/00001622-199511000-00013 |
0.328 |
|
| 1996 |
Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379: 88-91. PMID 8538748 DOI: 10.1038/379088A0 |
0.629 |
|
| 1996 |
Attardi LD, Lowe SW, Brugarolas J, Jacks T. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. The Embo Journal. 15: 3693-3701. DOI: 10.1002/J.1460-2075.1996.Tb00739.X |
0.779 |
|
| 1994 |
Lowe SW, Jacks T, Housman DE, Ruley HE. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proceedings of the National Academy of Sciences of the United States of America. 91: 2026-30. PMID 8134344 DOI: 10.1073/Pnas.91.6.2026 |
0.64 |
|
| 1994 |
Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, Dyke TV. p53-Dependent apoptosis suppresses tumor growth and progression in vivo Cell. 78: 703-711. PMID 8069917 DOI: 10.1016/0092-8674(94)90534-7 |
0.663 |
|
| 1994 |
Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science (New York, N.Y.). 266: 807-10. PMID 7973635 DOI: 10.1126/Science.7973635 |
0.668 |
|
| 1994 |
Lowe SW, Bodis S, Bardeesy N, McClatchey A, Remington L, Ruley HE, Fisher DE, Jacks T, Pelletier J, Housman DE. Apoptosis and the prognostic significance of p53 mutation. Cold Spring Harbor Symposia On Quantitative Biology. 59: 419-26. PMID 7587096 |
0.575 |
|
| 1994 |
Fisher DE, Bodis S, Lowe SW, Earl Ruley H, Housman DE, Jacks T. p53 dependnet sensitivity to radiation in a transplanted tumor model International Journal of Radiation Oncology*Biology*Physics. 30: 225. DOI: 10.1016/0360-3016(94)90749-8 |
0.564 |
|
| 1993 |
Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362: 847-9. PMID 8479522 DOI: 10.1038/362847A0 |
0.633 |
|
| 1993 |
Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74: 957-67. PMID 8402885 DOI: 10.1016/0092-8674(93)90719-7 |
0.643 |
|
| Show low-probability matches. |